The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Promising activity of KA2237 in R/R B-cell lymphoma
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results of the first-in-human, dose ascending, phase I study (NCT02679196) examining the safety and tolerability of KA2237, an oral inhibitor of the PI3K β and δ isoforms in patients with relapsed/refractory (R/R) B-cell lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
